•
Mar 31, 2021

Elanco Q1 2021 Earnings Report

Elanco reported better than expected results, building on the strong momentum since closing the Bayer Animal Health acquisition in August 2020.

Key Takeaways

Elanco's first quarter 2021 results exceeded expectations, driven by broad-based outperformance across categories and geographies. The company is updating its full year 2021 guidance, raising and tightening adjusted ranges.

Revenue was $1,242 million, an increase of 89 percent compared to the first quarter of 2020.

Global Pet Health business drove approximately half of the upside versus the midpoint of first quarter guidance.

Innovation pipeline is on track to yield eight launches in 2021.

Company completed the transition to its standalone ERP system during the first quarter.

Total Revenue
$1.24B
Previous year: $658M
+88.8%
EPS
$0.37
Previous year: $0.13
+184.6%
Gross Profit
$673M
Previous year: $325M
+107.1%
Cash and Equivalents
$515M
Previous year: $1.2B
-57.1%
Free Cash Flow
$4M
Previous year: -$9M
-144.4%
Total Assets
$17B
Previous year: $9.73B
+74.6%

Elanco

Elanco

Forward Guidance

Elanco is raising and tightening its full year 2021 guidance for revenue, adjusted EBITDA, and adjusted earnings per share.